You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Disease Modeling
Exposure and Bioavailability
Understanding the levels of systemic exposure following dosing is a critical component of drug discovery and development. Plasma samples can be taken at time points designed to answer your questions and analyzed to determine drug concentration and generate PK parameters. These PK parameters can provide valuable information to enable the selection of compounds with sufficient exposure and gain an understanding of the relationship between structure and exposure. Similarly, they can aid in the selection of the salt form of a compound or investigate different formulations. We can dose your drug intravenously to calculate the volume of distribution of your drug. A bioavailability study compares the systemic exposure achieved with a given route of administration with the exposure following IV dosing and determines the bioavailability of a therapeutic.
GD3 routinely runs these types of studies and can conduct both in vivo components and bioanalysis in-house, facilitating a rapid turn-around to advance your programs quickly.
Learn more about